Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 10/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 4/20 | 0.40 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185136 | 0.82 | RAB9A (0.40) | SYKRAB9AHSP90AA1SRCZAP70 | |
| SCHEMBL2184656 | 0.80 | RAB9A (0.49) | SYKRAB9AHSP90AA1SRCZAP70 | |
| SCHEMBL27911185 | 0.77 | RAB9A (0.43) | SYKRAB9AHSP90AA1SRCZAP70 | |
| SCHEMBL4902877 | 0.76 | RAB9A (0.61) | SYKRAB9AHSP90AA1SRCZAP70 | |
| SCHEMBL9865854 | 0.74 | HCAR1 (0.39) | — | |
| SCHEMBL29290793 | 0.73 | HSP90AA1 (0.48) | SYKRAB9AHSP90AA1SRCZAP70 | |
| SCHEMBL12367287 | 0.73 | SYK (0.39) | SYKRAB9AHSP90AA1SRCZAP70 | |
| SCHEMBL9287533 | 0.72 | CCR1 (0.54) | SYKRAB9AHSP90AA1SRCZAP70 | |
| SCHEMBL12367270 | 0.70 | HTR7 (0.36) | — | |
| SCHEMBL2956514 | 0.69 | MIF (0.54) | RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735424-B2 | Bicyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-05-27 | — | — | US | disclosed |
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | SYK 552/4885RAB9A 3490/4885HSP90AA1 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.